Updates are available Correction dated 2024-12-11
Click to view Correction: https://doi.org/10.1007/s00125-024-06317-y
-
Authors
Perkins, Bruce A. https://orcid.org/0000-0002-5885-0046
Turner, Lauren V. https://orcid.org/0000-0002-3882-4123
Riddell, Michael C. https://orcid.org/0000-0001-6556-7559
- License Information
-
More Information
Article History
Received: 5 March 2024
Accepted: 28 May 2024
First Online: 15 August 2024
Change Date: 11 December 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00125-024-06317-y
Funding
: No funding was received for the writing of this review. BAP is supported by the Sam and Judy Pencer Family Chair in Diabetes Clinical Research at the University of Toronto. LVT is supported by a Canadian Institute for Health Research Canada Graduate Scholarship and by an Innovation York Commercialisation Fellowship for her work on Excarbs.net with MCR.
: BAP has received speaker honoraria from Abbott, Medtronic, Insulet, Sanofi and Novo Nordisk; has received research support to his research institute from Novo Nordisk and the Bank of Montreal (BMO); and has served as a consultant to Abbott, Insulet, Novo Nordisk, Sanofi, Vertex and Nephris. MCR reports receiving consulting fees from the Jaeb Center for Health Research, Eli Lilly, embecta, Zealand Pharma and Zucara Therapeutics; speaker fees from Sanofi Diabetes, Eli Lilly, Dexcom Canada and Novo Nordisk; and stock options from Supersapiens and Zucara Therapeutics. LVT declares that there are no relationships or activities that might bias, or be perceived to bias, her work
: All authors contributed to the drafting and completion of this manuscript, including approval of the version for publication.
